Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A

NCT03950297 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: 609A

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.